Overview

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients.

Phase:

Phase 4

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa